External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis.
breast cancer
micro-metastases
sentinel node
trial
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 10 2020
11 10 2020
Historique:
received:
04
09
2020
revised:
05
10
2020
accepted:
07
10
2020
entrez:
14
10
2020
pubmed:
15
10
2020
medline:
15
10
2020
Statut:
epublish
Résumé
Many trials confirmed the safety of omitting axillary dissection in the selected patients treated for early breast cancer. The external validity of these trials is questionable. Our study aimed to evaluate the accuracy of the French population representativity in the SERC trial and the differences between these two populations as well as comparing the French and the Swedish populations (the SENOMIC trial population and the Swedish National Breast Cancer Registry (NKBC) cohort) of patients with sentinel node (SN) micro-metastasis. A higher rate of smaller tumors and grade 1 tumors was observed in the French cohort when compared to the SERC population. Our findings conclude that both French populations show similar characteristics. Positive non-sentinel node (NSN) rates at completion axillary lymph node dissection (ALND) were 10.28 % and 11.3 % in the SERC trial and French cohort, respectively (
Identifiants
pubmed: 33050650
pii: cancers12102924
doi: 10.3390/cancers12102924
pmc: PMC7600229
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Clin Oncol (R Coll Radiol). 2015 Dec;27(12):692-5
pubmed: 26254841
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
Lancet Oncol. 2018 Oct;19(10):1385-1393
pubmed: 30196031
J Clin Oncol. 2014 Dec 1;32(34):3901-2
pubmed: 25245448
Geburtshilfe Frauenheilkd. 2017 Feb;77(2):149-157
pubmed: 28331237
Bull Cancer. 2014 Apr;101(4):358-63
pubmed: 24793627
Breast Cancer Res Treat. 2019 Sep;177(2):469-475
pubmed: 31236811
BMC Cancer. 2017 May 26;17(1):379
pubmed: 28549453
Eur J Cancer. 2016 May;58:73-82
pubmed: 26971077
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
BMC Cancer. 2018 Nov 21;18(1):1153
pubmed: 30463611
World J Clin Oncol. 2015 Feb 10;6(1):1-6
pubmed: 25667909
Trials. 2015 Nov 03;16:495
pubmed: 26530985
Ann Surg Oncol. 2013 Jan;20(1):120-7
pubmed: 22956062
Ann Surg Oncol. 2011 Sep;18(9):2407-12
pubmed: 21327455
J Clin Oncol. 2014 Dec 1;32(34):3902
pubmed: 25245444
Lancet Oncol. 2013 Apr;14(4):297-305
pubmed: 23491275
Breast. 2016 Dec;30:197-200
pubmed: 27406897
Lancet Oncol. 2010 Oct;11(10):927-33
pubmed: 20863759
Adv Radiat Oncol. 2018 Apr 24;3(3):258-264
pubmed: 30197938
J Clin Oncol. 2014 Dec 1;32(34):3902-4
pubmed: 25245450
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663